Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy) [AID624097, Type: other]

View

X

Row No.

1

Structure

Substance

SID

125264855

CID

53362017

Outcome

Chemical Probe

MIC [4 fold reduction]

0.781 [uM]

BioAssay

Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy)

Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit IMP-1 [AID624084, Type: confirmatory]

View

X

Row No.

2

Structure

Substance

SID

134220672

CID

53362017

Outcome

Chemical Probe

Ki

0.93 [uM]

BioAssay

Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit IMP-1

Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit IMP-1 [AID624085, Type: confirmatory]

View

X

Row No.

3

Structure

Substance

SID

125264855

CID

53362017

Outcome

Chemical Probe

IC50

3.018 [uM]

BioAssay

Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit IMP-1

Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy) [AID624097, Type: other]

View

X

Row No.

5

Structure

Substance

SID

131269027

CID

54579797

Outcome

Active

MIC [4 fold reduction]

0.781 [uM]

BioAssay

Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy)

Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy) [AID624097, Type: other]

View

X

Row No.

6

Structure

Substance

SID

126723253

CID

53495082

Outcome

Active

MIC [4 fold reduction]

0.781 [uM]

BioAssay

Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy)

Late stage results from the probe development effort to identify common IMP-1 and VIM-2 inhibitors: Epi-absorbance-based biochemical dose response assay for inhibitors of IMP-1metallo-beta-lactamase [AID2768, Type: confirmatory]

View

X

Row No.

8

Structure

Substance

SID

92192482

CID

45105306

Outcome

Active

IC50

1.327 [uM]

BioAssay

Late stage results from the probe development effort to identify common IMP-1 and VIM-2 inhibitors: Epi-absorbance-based biochemical dose response assay for inhibitors of IMP-1metallo-beta-lactamase

Late stage results from the probe development effort to identify common IMP-1 and VIM-2 inhibitors: Epi-absorbance-based biochemical dose response assay for inhibitors of IMP-1metallo-beta-lactamase [AID2768, Type: confirmatory]

View

X

Row No.

9

Structure

Substance

SID

92192480

CID

10448266

Outcome

Active

IC50

1.507 [uM]

BioAssay

Late stage results from the probe development effort to identify common IMP-1 and VIM-2 inhibitors: Epi-absorbance-based biochemical dose response assay for inhibitors of IMP-1metallo-beta-lactamase

Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy) [AID624097, Type: other]

View

X

Row No.

10

Structure

Substance

SID

125311278

CID

53384679

Outcome

Active

MIC [4 fold reduction]

1.563 [uM]

BioAssay

Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy)

Late stage results from the probe development effort to identify common IMP-1 and VIM-2 inhibitors: Epi-absorbance-based biochemical dose response assay for inhibitors of IMP-1metallo-beta-lactamase [AID2768, Type: confirmatory]

View

X

Row No.

12

Structure

Substance

SID

92192478

CID

45105304

Outcome

Active

IC50

1.806 [uM]

BioAssay

Late stage results from the probe development effort to identify common IMP-1 and VIM-2 inhibitors: Epi-absorbance-based biochemical dose response assay for inhibitors of IMP-1metallo-beta-lactamase

Late stage results from the probe development effort to identify common IMP-1 and VIM-2 inhibitors: Epi-absorbance-based biochemical dose response assay for inhibitors of IMP-1metallo-beta-lactamase [AID2768, Type: confirmatory]

View

X

Row No.

14

Structure

Substance

SID

92192479

CID

45105307

Outcome

Active

IC50

2.33 [uM]

BioAssay

Late stage results from the probe development effort to identify common IMP-1 and VIM-2 inhibitors: Epi-absorbance-based biochemical dose response assay for inhibitors of IMP-1metallo-beta-lactamase

Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy) [AID624097, Type: other]

View

X

Row No.

17

Structure

Substance

SID

124767346

CID

53308605

Outcome

Active

MIC [4 fold reduction]

3.125 [uM]

BioAssay

Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy)

Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy) [AID624097, Type: other]

View

X

Row No.

18

Structure

Substance

SID

126723255

CID

53495083

Outcome

Active

MIC [4 fold reduction]

3.125 [uM]

BioAssay

Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective):IMP-1-transformed E. coli growth inhibition in the presence of imipenem (synergy)